Equities

DNA Group (T.R.) Ltd

DNA:TLV

DNA Group (T.R.) Ltd

Actions
Health CareMedical Equipment and Services
  • Price (ILa)84.00
  • Today's Change1.00 / 1.20%
  • Shares traded98.71k
  • 1 Year change+5.00%
  • Beta0.9794
Data delayed at least 20 minutes, as of May 01 2024 15:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DNA Group TR Ltd, former DNA Biomedical Solutions Ltd, is an Israel-based company, which is engaged in the biotechnology sector. The Company's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltd’s proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltd’s drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.

  • Revenue in ILS (TTM)306.00k
  • Net income in ILS-1.18m
  • Incorporated2004
  • Employees14.00
  • Location
    DNA Group (T.R.) LtdSHIM'ON HATARSI 43TEL AVIV-YAFO 62492IsraelISR
  • Phone+972 35462550
  • Fax+972 35462570
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kadimastem Ltd0.00-12.01m20.65m32.00---------1.22-1.220.00-1.040.00-------115.17-155.33-1,153.60-1,831.12-----------9.443.22------47.14---50.73--
Nextage Therapeutics Ltd876.00k-4.07m26.28m--------30.00-0.1396-0.13960.03-0.09580.672--6.82---322.44-188.94---423.7625.6833.33-479.79-2,486.19---18.46------17.9927.21------
Cannassure Therapeutics Ltd11.00m-1.18m29.71m------106.872.70-1.43-2.1613.28-3.660.53291.374.47---5.74-45.39-18.34-92.4129.17---10.77-83.490.04740.9011-----67.44--78.37---72.23--
Tikun Olam Cannbit Pharmaceuticals Ltd44.23m-88.89m33.39m51.00--0.7781--0.755-1.43-1.430.70180.50510.3792.8719.85867,215.70-80.56-30.17-99.81-35.04-0.4273---212.57-146.420.5033-30.020.3778---10.28---84.28---8.71--
Can Fite Biopharma Ltd2.77m-28.45m38.67m5.00--1.51--13.96-0.0226-0.02260.00220.01710.0771----553,891.60-79.22-102.29-103.51-131.07-----1,027.46-1,105.36----0.00---8.27-27.9224.96---42.92--
Grace Breeding Ltd463.00k-8.50m44.02m----27.77--95.08-2.36-2.250.12960.39980.08482.730.9636---164.09---206.24--80.56---1,935.21--1.45-94.740.5103--121.53--23.10------
Wilk Technologies Ltd0.00-10.93m47.89m4.00--6.93-----0.1807-0.18070.000.10060.00-------80.10-266.55-96.15-298.65-------97,340.88---39.620.4049------36.02------
X T L Biopharmaceuticals Ltd1.69m-83.83m50.89m33.00--0.6073--30.07-0.3806-0.38060.00770.15380.0192--0.701251,279.99-94.96-53.17-111.98-59.10---2.33-4,953.75-1,084.42----0.00---85.80---7.97---53.12--
Purple Biotech Ltd0.00-74.10m54.22m20.00--0.413-----0.3158-0.31580.000.50520.00----0.00-40.39-37.24-47.34-41.28-------9,415.70----0.0101------8.25---28.45--
Matricelf Ltd0.00-13.83m70.80m----2.64-----0.8777-0.87770.001.670.00-------39.69---42.80--------------0.0527-------10.77------
DNA Group TR Ltd306.00k-1.18m100.13m14.00--1.26--327.23-0.0088-0.00880.00250.64290.0038--1.3721,857.14-1.45-23.54-1.46-26.27-----384.64-7,406.24----0.00---45.36--95.00------
GFC Green Fields Capital Ltd0.0015.70m117.65m2.007.520.74337.50--1.561.560.0015.770.00------3.261.9910.383.58------------0.00------844.9045.32----
BioLine RX Ltd17.89m-225.93m209.66m79.00--3.85--11.72-0.2363-0.23630.01860.04540.0684--5.03226,474.90-86.40-52.74-122.73-65.4323.08---1,262.79-3,501.791.47-425.650.4671-------142.93---50.72--
Data as of May 01 2024. Currency figures normalised to DNA Group (T.R.) Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

0.53%Per cent of shares held by top holders
HolderShares% Held
Sigma Mutual Funds Ltd.as of 31 Jan 2024463.01k0.38%
Meitav Mutual Funds Ltd.as of 31 Jan 2024100.98k0.08%
Migdal Mutual Funds Ltd.as of 31 Jan 202432.92k0.03%
Sigma PCM Mutual Funds Management Co. Ltd.as of 31 Dec 202328.12k0.02%
KSM Mutual Funds Ltd.as of 31 Jan 202418.37k0.02%
Psagot Mutual Funds Ltd.as of 29 Feb 20249.76k0.01%
Harel Mutual Funds Ltd.as of 31 Jan 20243.44k0.00%
More ▼
Data from 31 Dec 2023 - 31 Jan 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.